King Pharmaceuticals KG Legacy Reinsurance — Restricted Cash and Investments

Similar metrics at other companies

RMLife Insurance — Restricted Cash And Investments

$23.1M+9.0%

RYNRestricted Cash and Investments

$495K-26.9%

SLMRestricted Cash and Investments

$223.92M+29.1%

FPHRestricted Cash and Investments

$992K0.0%

RSGRestricted Cash and Investments

$292M+31.5%

WMRestricted Cash and Investments

$654M+18.1%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's legacy reinsurance — restricted cash and investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's legacy reinsurance — restricted cash and investments?: King Pharmaceuticals (KG) reported legacy reinsurance — restricted cash and investments of $159.5M in Q1 2026.
What does legacy reinsurance — restricted cash and investments mean?: Cash and investment balances within the Legacy Reinsurance segment that are subject to legal or contractual restrictions, such as collateral requirements or regulatory mandates. These assets are not available for general corporate use and indicate specific liquidity commitments.